America’s biopharmaceutical research companies are investigating or developing 93 medicines to help the more than five million patients in the United States who are living with Alzheimer’s. The medicines in development – all in either clinical trials or under review by the Food and Drug Administration – include 81 for Alzheimer’s, 11 for cognition disorders and 2 for dementias, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Alzheimer’s is one of the most complex diseases researchers have ever studied. There are many reasons Alzheimer’s research is so challenging. To start, the brain is the most complex and inaccessible organ in the body and the disease is correspondingly complicated. However, as our understanding of the disease grows so does our ability to find new potential treatment approaches and, ultimately, effective new medicines.
“Alzheimer’s disease prevents those affected from fighting for themselves, so it’s up to all of us to fight on their behalf,” said PhRMA President and CEO John J. Castellani. “Confronting this devastating disease of the brain will require continued collaboration in the scientific, medical and patient care communities and a commitment by policymakers to support and reward medical innovation.”